Repair

ARA-290 Peptide Protocol & Dosing

Updated 2mo ago 6 min read 178+ helpful Calculator

Validity Score

72 Usable

Evidence 80

Community 70

Completeness 57

Actionability 60

Coverage 80

Penalty -0

This score combines formal evidence, page completeness, calculator readiness, and community convergence.

What it is

ARA-290, also called cibinetide, is an EPO-derived tissue-protective peptide studied for neuropathic pain and small fiber nerve loss.

Evidence boundary

Investigational / limited human evidence.

Trial evidence

PMID 25387363 — ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.
PMID 24136731 — ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.
PMID 28475703 — Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.
PMID 24555851 — ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

Preparation and measurement

Reconstitution: 16 mg vial + 2 mL BAC = 8 mg/mL.

Concentration matches.

Reference schedule

Reference schedule
Phase	Dose	Draw / measure	Frequency	Weekly total
Week 1 (titration)	2 mg	25 U (0.25 mL)	Daily during cycle	14 mg/week
Weeks 2–8 (target)	4 mg	50 U (0.5 mL)	Daily during cycle	28 mg/week

Week 1 (titration)

Dose: 2 mg
Draw / measure: 25 U (0.25 mL)
Frequency: Daily during cycle
Weekly total: 14 mg/week

Weeks 2–8 (target)

Dose: 4 mg
Draw / measure: 50 U (0.5 mL)
Frequency: Daily during cycle
Weekly total: 28 mg/week

Weekly totals apply only during the active phase.

Titration rules

Standard (4 mg/day): Phase 2 trial dose.
Cycle: 28 days active per Phase 2 protocol; longer protocols (8–12 weeks) used in chronic-condition research.
Neuropathic pain or numbness
Corneal nerve fiber symptoms in sarcoidosis
Tolerability
Injection-site reactions

Practical rules

Rotate sites if it is being compared in notes.
Don’t expand it into erythropoietic use.

Was this protocol helpful?

Share via

Dosing references

Peptide dosage chart Peptide dose calculator Syringe mixability

Related protocols

KPV Peptide Protocol & Dosing BPC-157 Peptide Protocol & Dosing GHK-Cu Peptide Protocol & Dosing LL-37 Peptide Protocol & Dosing

Supply & lot verification Availability and batch-linked COA records for ARA-290 Peptide Protocol & Dosing are tracked with the current supplier listings. View availability & COA →

Dosing Calculator

10 mg + 2 mL BAC · week 1 2 mg

LIVE CALCULATIONvolume / concentration / draw

RP–CALC–01

01 Vial size

02 BAC water

DRAW AMOUNT40 units0.4 mL · U-100

Draw 40 units, equivalent to 0.4 milliliters.

Concentration5 mg/mL

Selected dose2 mg = 40 units

04 Custom dose

05 Standard amounts

1–10 mg · 0.5 mg steps

06 Suggested doses Select a row

1 unit = 0.01 mL on a U-100 syringe. Values retain decimal precision; visual marks are not silently snapped.

07 cycle summary

Vials required for Cycle

Estimate how much material you need for a full cycle, including cycle length and the number of cycles you plan to run.

Cycle length (weeks) Injections per week Number of cycles

Cycle total —

Total required vials —

Total reconstitution —

Total BAC water —

08 projected levels

How the draws stack up

A first-order model of depot absorption and elimination, run on the draws and cadence above. Pick the half-life from whatever your own source documents — this page does not assume one per compound. A planning sketch — not a prediction for any compound or any individual.

Half-life

Hours

Modelled level across the cycle. Each spike is one draw.

Accumulation—steady state vs one draw

Peak-to-trough—inside one interval

Steady state—about 4 half-lives

Draws modelled—at this cadence

Vial yieldat the selected amount

Draws per vial—

Lasts—

Volume used—

Limiting factor—

Water matrixsame vial, same amount

WaterStrengthDraw

0.5 mL——

1 mL——

2 mL——

3 mL——

5 mL——